Adamis, DMK Pharmaceuticals to Merge

 

• Combined company will have commercial products and a library of development candidates, two of which are clinical stage
  
  

• Will be under the leadership of DMK CEO, Dr. Ebrahim (Eboo) Versi MD, PhD
  
  

• Lead development program will be a clinical stage therapeutic under development for the treatment of opioid use disorder

On February 24, 2023, Adamis entered into the Agreement with DMK and Aardvark Merger Sub (“Merger Sub”), a newly created wholly-owned subsidiary of Adamis, pursuant to which DMK will merge with and into Merger Sub (the “Merger”), with Merger Sub as the surviving corporation of the Merger and a wholly owned subsidiary of Adamis.

Subject to approval by the Adamis stockholders of proposals relating to the transaction and the satisfaction of other closing conditions, in connection with and before the effective time of the Merger (the “Effective Time”), a reverse stock split of Adamis Common Stock will be consummated, pursuant to which a number of outstanding shares of Adamis Common Stock (determined by the Reverse Stock Split Ratio) will be converted into one share of Adamis Common Stock at a ratio to be determined by the Adamis board of directors.

Please see Adamis Report on Form 8-K which will be filed with the Securities and Exchange Commission for additional detail on the proposed transaction.

https://finance.yahoo.com/news/adamis-pharmaceuticals-dmk-pharmaceuticals-announce-210500709.html